Navigation Links
Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015-2019
Date:2/9/2016

LONDON, Feb. 9, 2016 /PRNewswire/ -- The new report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - 2019" by Spearhead Acuity Business Research & Consulting group reveals that the North America continued to lead global anti-bacterial drugs market with a share of 38.9% in 2014 that translated into revenues worth US$ 16,907.3 million.

The report analyzes the global anti-bacterial drugs market in six regions of North America, Europe, Asia-Pacific, Latin America, Middle-East and Africa. The global anti-bacterial market is inclined towards North America and Europe. The majority can be attributed to large volume generic sales as well as a strongest innovative R&D activity in the sector with a large number of companies such as Cubist Pharmaceuticals, Cempra, Actelion, Achaogen and Melinta. Europe and Asia-Pacific followed with market shares of 24.7% and 18.7% respectively. Asia-Pacific is expected to overtake Europe with expirations of several drugs that will be absorbed by the strong generics market by the end of this decade. China remains the largest supplier of raw materials and active moiety to drug manufacturers over the world. With emerging countries such as India and China, the Asia-Pacific region is expected to remain a major threat to innovators and originator companies developing new drugs.

In light of the recent violent clashes throughout different regions of Europe and unpredicted future in conflict regions such as Ukraine and Syria have taken considerable toll in investments for healthcare and progress. There are several initiatives that continue to support the development such as the New Drugs for Bad Bugs (ND4BB) initiative and the IMI-funded COMBACTE project, which aims to give antibiotic drug development a much-needed boost by pioneering new ways of designing and implementing efficient clinical trials for novel antibiotics. These initiatives will drive the innovation of the drugs market in coming years. Price fixing also tends to restrict revenues in the region and other challenges include regulatory hurdles such that new drugs need to show non-inferiority in clinical trials within a margin of 10% as compared with current gold standards.

This report covers major anti-bacterial drug brands by 18 major companies such as Merck & Co, Pfizer Inc, Cubist Pharmaceuticals, Cempra Pharmaceuticals, Astrazeneca, Forest Pharmaceuticals, Actavis, Johnson & Johnson (Janssen Pharma), Mpex Pharmaceuticals Inc, GlaxoSmithKline plc, Takeda, Durata Pharmaceuticals, Targanta, Nektar, Paratek, The Medicines Company, Melinta and Optimer. This exhaustive report covers existing brands such as Cubicin (daptomycin), Teflaro/Zinforo (ceftaroline), Dificid (fidaxomicin), Dalvance (dalbavancin), Orbactiv (oritavancin), Sivextro (tedizolid), Zerbaxa (ceftolozane + tazobactam), Avycaz (ceftazidime-avibactam), Zyvox (linezolid), Avelox (moxifloxacin), Augmentin (amoxicillin + clavulanic acid), Zosyn/Tazocin (piperacillin + tazobactam), Invanz (ertapenem), Tygacil (tigecyline). The scope also covers analysis of stage three and stage two pipeline drugs such as Surotomycin, Solitaire (solithromycin), Delafloxacin, Plazomycin, Taksta (fusidic acid), Cadazolid, Carbavance, Eravacycline, Finafloxacin, Omadacycline, Zabofloxacin, Ramoplanin, Nemonoxacin and Relebactam (MK-7655).

Until recently, the anti-bacterial pipeline was considered to be completely dry with very few foreseen launches, however 2014-2015 saw five major launches with another 8 expected by the turn of the decade. The largest challenge for drug manufacturers was to overcome a barrage of highly drug-resistant superbugs that have been observed across hospitals across the world. Improper usage, dosage and treatment regimen followed by patients has now created significant damage in terms of health since drug-resistant bacteria are difficult to deal with using conventional pharmaceuticals. Consistent investment in research and development particularly by early-clinical stage companies has been successful in delivering a sustainable pipeline for the market. Several companies such as Cellceutix have expanded into the anti-bacterial market after discovery of effective lead compounds against highly difficult to treat pan-drug resistant microbes. Macrolides are expected to become the fastest growing segment within the anti-bacterial space in coming years.

Download the full report: https://www.reportbuyer.com/product/3605164/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com


'/>"/>
SOURCE ReportBuyer
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Latest developments in cancer research and treatment explored by top global scientists at Tucson Symposium
2. Global Skin Protective Equipment Market 2016-2020 - Key Vendors are 3M, Ansell, Drager, Grolls & Kimberly-Clark
3. Intarcia Appoints Dr. John Yee into New Role of VP, Global Medical Affairs, Safety and Operations, Reporting Directly to Chairman & CEO Kurt Graves
4. Knee Reconstruction Devices Market Projected to Reach USD 7.94 Billion by 2020 - Global Analysis and Forecasts
5. Global Label-Free Detection Market Value of USD 2.13 Billion by 2020 - Analysis, Trends & Opportunities 2016-2020 - Key Vendors: Attana AB, Bio-Rad & Danaher
6. Amgen To Present At The Leerink Partners 5th Annual Global Healthcare Conference
7. Syneron Medical to Participate in Leerink Partners 5th Annual Global Healthcare Conference
8. Global Musculoskeletal Partnering Deals Analysis 2010-2016
9. Global Obstetrics Partnering Deal Trends, Players and Financials Breakdown 2010-2016
10. Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth
11. Global Viral Partnering Deal Trends, Players and Financials Analysis Report 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... LONDON , Sept. 5, 2017  Just 18 ... Valid Insight is pleased to announce the appointment of ... Tammy Wynne , Dominic Jones-Phillips and ... from industry. ... a team of market access writers. She has over ...
Breaking Medicine Technology:
(Date:9/21/2017)... Va. (PRWEB) , ... September 21, 2017 , ... ... with a different approach to addiction recovery at a time when Virginia faces ... deaths resulting from drug overdose, a staggering increase of 38 percent from 2015, ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... the acquisition of Isle at Kingwood Assisted Living and Memory Care located at ... retirement community with 55 assisted living apartments, 43 memory care apartments and 23 ...
(Date:9/21/2017)... ... September 21, 2017 , ... In ... and Clark College Emeritus Professor of Education Gregory A. Smith examines student privacy ... Asleep at the Switch: Schoolhouse Commercialism, Privacy, and the Failure of Policymaking . ...
(Date:9/20/2017)... CHARLOTTE, NC (PRWEB) , ... September 20, 2017 ... ... for Transformation and Centers of Excellence (CoE) with the latest Artificial Intelligence (AI) ... newly designed presence offers quick and easy access to essential information that offers ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... one of the Best Places to Work in the Research Triangle for 2017. ... Once nominated, a company had to meet a threshold in employee participation--a percentage ...
Breaking Medicine News(10 mins):